EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Akari Therapeutics, Plc - AKTX

NEW YORK, July 5, 2017

To join the Akari Therapeutics class action, go to http://www.rosenlegal.com/cases-1127.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Akari Therapeutics's CEO, and possibly other executives, were involved in publishing false information about Akari Therapeutics, including false information about the Phase 2 PNH trial of Coversin; (2) Akari Therapeutics lacked adequate checks and protections to prevent such behavior; and (3) as a result, defendants' statements about Akari Therapeutics' business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1127.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.